1. Home
  2. |Insights
  3. |DoD Issues Reminder on Ins/Outs the GSA FSS

DoD Issues Reminder on Ins/Outs the GSA FSS

Client Alert | less than 1 min read | 08.10.15

The Director of Defense Procurement and Acquisition Policy recently issued guidance to prepare DoD’s contracting workforce for the increase in GSA FSS procurements that generally take place as the fiscal year comes to a close. This "reminder" reiterates the requirement that contracting officers must make their own determination of price reasonableness and outlines the standard procedures to follow, including the requirements for DoD to seek additional discounts and to maximize competition when placing orders through GSA FSS.


Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights